Hye Jin Yoo

Dr. Hye Jin Yoo


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2010 in Diabetes Care
Verified
Journal Article
Open access
TKTae Nyun Kim
Tae Nyun Kim
MPMan Sik Park
Man Sik Park
SYSae Jeong Yang
Sae Jeong Yang
HYHye Jin Yoo
Hye Jin Yoo
HKHyun Joo Kang
Hyun Joo Kang
KCKyung Mook Choi
Kyung Mook Choi
OBJECTIVE: We examined prevalence of sarcopenia in Korean patients with type 2 diabetes and compared body compositional parameters between subjects with and without type 2 diabetes. RESEARCH DESIGN AND METHODS: The Korean Sarcopenic Obesity Study (KSOS) included 810 subjects (414 patients with diabetes and 396 control subjects) who were examined using dual-energy X-ray absorptiometry. Prevalence of sarcopenia was defined using the skeletal muscle index (SMI). RESULTS: Prevalence in patients with diabetes and in the control group was 15.7 and 6.9%, respectively. In both men and women, SMI values were significantly decreased in patients with diabetes compared with subjects without diabetes. Furthermore, multiple logistic regression analysis showed that type 2 diabetes was independently associated with sarcopenia. CONCLUSIONS: Type 2 diabetes was associated with increased risk of sarcopenia. These characteristics may contribute to physical disability and metabolic disorders in older adults with diabetes.

31 August 2013 in Hepatology
Verified
Journal Article
Open access
PDF file
HHHo Cheol Hong
Ho Cheol Hong
SHSoon Young Hwang
Soon Young Hwang
HCHae Yoon Choi
Hae Yoon Choi
HYHye Jin Yoo
Hye Jin Yoo
JSJi A Seo
Ji A Seo
KCKyung Mook Choi
Kyung Mook Choi
Previous studies have shown that nonalcoholic fatty liver disease (NAFLD) and sarcopenia may share pathophysiological mechanisms, such as insulin resistance, inflammation, vitamin D deficiency, and decreased physical activity. However, their direct relationship has not been investigated. The association between NAFLD and sarcopenia was examined in 452 apparently healthy adults enrolled in the Korean Sarcopenic Obesity Study (KSOS), an ongoing prospective observational cohort study. The liver attenuation index (LAI), which was measured using abdominal computed tomography (CT), was used as a parameter for the diagnosis of NAFLD. Sarcopenia was defined using a skeletal muscle mass index (SMI) [SMI (%) = total skeletal muscle mass (kg) / weight (kg) × 100] that was measured by dual energy X-ray absorptiometry (DXA). After adjusting for age and sex, both SMI and LAI were negatively correlated with the homeostasis model assessment of insulin resistance (HOMA-IR) ( P < 0.001) and high sensitivity C-reactive protein (hsCRP) ( P < 0.001) as well as brachial-ankle pulse wave velocity (baPWV), an indicator of arterial stiffness. Furthermore, SMI and LAI had positive relationships with high-density lipoprotein (HDL)-cholesterol, but both had a negative relationship with triglyceride, alanine aminotransferase (ALT), and total body fat. In a multiple logistic regression analysis, the odds ratio for NAFLD risk was 5.16 (95% confidence interval [CI] = 1.63-16.33) in the lowest quartile of SMI compared to the highest after adjusting for potential confounding factors. Conclusion : Individuals with lower muscle mass exhibited increased risk of NAFLD. This result may provide a novel insight into the mechanism linking between sarcopenia and NAFLD. (Clinical trial no. NCT01594710.) (Hepatology 2014;59:1772–1778)

1 April 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
JYJi Hee Yu
Ji Hee Yu
CYChang-Ho Yun
Chang-Ho Yun
JAJae Hee Ahn
Jae Hee Ahn
SSSooyeon Suh
Sooyeon Suh
HCHyun Joo Cho
Hyun Joo Cho
NKNan Hee Kim
Nan Hee Kim
Chronotype is a trait determining individual circadian preference in behavioral and biological rhythm relative to external light-dark cycle. However, little is known about the relationship between chronotype and metabolic disorders. The aim of this study was to examine whether late chronotype is related to metabolic abnormalities and body composition in middle-aged adults, independent of sleep duration and lifestyle. A total of 1620 participants aged 47-59 years were recruited from the Korean Genome and Epidemiology Study. Chronotype was assessed by the Morningness-Eveningness Questionnaire. Associations of chronotype with diabetes, metabolic syndrome, sarcopenia, and visceral obesity were analyzed. All participants underwent the oral glucose tolerance test, and body composition was measured with dual energy x-ray absorptiometry. Visceral obesity was designated as visceral fat area, measured by abdominal computed tomography, of >100 cm(2). Chronotype was classified as morning in 29.6% of subjects, evening in 5.9%, neither morning nor evening in 64.5%. Evening type, when compared with morning type, was significantly associated with diabetes (odds ratio [OR], 1.73; 95% confidence interval [CI], 1.01-2.95), metabolic syndrome (OR, 1.74; 95% CI, 1.05-2.87), and sarcopenia (OR, 3.16; 95% CI, 1.36-7.33) after adjusting for confounding factors. Gender differences in the associations were evident. In men, evening type was associated with diabetes (OR, 2.98; 95% CI, 1.39-6.39) and sarcopenia (OR, 3.89; 95% CI, 1.33-11.33). Only metabolic syndrome was associated with evening type in women (OR, 2.22; 95% CI, 1.11-4.43). At the population level, evening chronotype was independently associated with diabetes, metabolic syndrome, and sarcopenia. These results support the importance of circadian rhythms in metabolic regulation.

1 October 2008 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
HYHye Jin Yoo
Hye Jin Yoo
HAH.G. An
H.G. An
SPS.Y. Park
S.Y. Park
ORO.H. Ryu
O.H. Ryu
HKH.Y. Kim
H.Y. Kim
SBS.H. Baik
S.H. Baik

7 May 2012 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
TKTae Nyun Kim
Tae Nyun Kim
MPMan Sik Park
Man Sik Park
KLKang Il Lim
Kang Il Lim
HCHae Yoon Choi
Hae Yoon Choi
SYSae Jeong Yang
Sae Jeong Yang
KCKyung Mook Choi
Kyung Mook Choi

1 August 2011 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
SYS. J. Yang
S. J. Yang
SHS. Y. Hwang
S. Y. Hwang
HCH. Y. Choi
H. Y. Choi
HYHye Jin Yoo
Hye Jin Yoo
JSJ. A. Seo
J. A. Seo
KCKyung Mook Choi
Kyung Mook Choi
The dysregulation of hepatokines may be associated with the pathogenesis of insulin resistance and type 2 diabetes. A recent study has suggested that selenoprotein P (SeP), a novel hepatokine, may play a role in the regulation of glucose metabolism and insulin sensitivity. We examined the relationship between circulating SeP levels and clinical parameters associated with insulin resistance in humans. We compared serum SeP concentrations in 100 subjects with diverse glucose tolerance statuses. Furthermore, we evaluated the relationship between SeP and cardiometabolic risk factors including insulin resistance, high-sensitivity C-reactive protein, and carotid intima-media thickness. Serum SeP concentrations were significantly higher in patients with type 2 diabetes or prediabetes than those with normal glucose tolerance (all P < 0.01) and decreased in a stepwise manner [1032.4 (495.9-2149.4) vs. 867.3 (516.3-1582.7) vs. 362.0 (252.5-694.5), P = 0.004]. In addition, overweight and obese subjects had significantly increased SeP levels compared with lean subjects (P = 0.002). Spearman's partial correlation analysis adjusted for age and gender showed a significant relationship between SeP and cardiometabolic factors including body mass index, waist circumference, systolic blood pressure, triglycerides, glucose, hemoglobin A1c, aspartate aminotransferase, and insulin resistance. Furthermore, in multiple regression analyses, SeP showed an independent association with carotid intima-media thickness as well as high-sensitivity C-reactive protein, even after adjustment for other confounding factors. Circulating SeP concentrations were elevated in patients with glucose metabolism dysregulation and were related to various cardiometabolic parameters including insulin resistance, inflammation, and atherosclerosis.